FDA staff recommends Novartis copy of Amgen's Neupogen

(Reuters) - Staff reviewers at the U.S. Food and Drug Administration recommended approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, finding no "clinically meaningful differences" between the two.

Source: Reuters: Health - January 5, 2015 Category: Consumer Health News Tags: healthNews Source Type: news